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Rift Valley Fever Virus (RVFV) is a RNA virus that belongs to the genus Phlebovirus,
family Bunyaviridae. It infects humans and livestock and causes Rift Valley fever. RVFV
is considered an agricultural pathogen by the USDA, as it can cause up to 100%
abortion in cattle and extensive death of newborns. In addition, it is designated as
Category A pathogen by the CDC and the NIAID. In some human cases of RVFV
infection, the virus causes fever, ocular damage, liver damage, hemorrhagic fever, and
death. There are currently limited options for vaccine candidates, which include the
MP-12 and clone 13 versions of RVFV. Viral infections often deregulate multiple cellular
pathways that contribute to replication and host pathology. We have previously shown
that latent human immunodeficiency virus-1 (HIV-1) and human T-cell lymphotropic
virus-1 (HTLV-1) infected cells secrete exosomes that contain short viral RNAs, limited
number of genomic RNAs, and viral proteins. These exosomes largely target neighboring
cells and activate the NF-κB pathway, leading to cell proliferation, and overall better viral
replication. In this manuscript, we studied the effects of exosome formation from RVFV
infected cells and their function on recipient cells. We initially infected cells, isolated
resistant clones, and further purified using dilution cloning. We then characterized these
cells as resistant to new RVFV infection, but sensitive to other viral infections, including
Venezuelan Equine Encephalitis Virus (VEEV). These clones contained normal markers
(i.e., CD63) for exosomes and were able to activate the TLR pathway in recipient
reporter cells. Interestingly, the exosome rich preparations, much like their host cell,
contained viral RNA (L, M, and S genome). The RNAs were detected using qRT-PCR
in both parental and exosomal preparations as well as in CD63 immunoprecipitates.
Viral proteins such as N and a modified form of NSs were present in some of these
exosomes. Finally, treatment of recipient cells (T-cells and monocytic cells) showed
drastic rate of apoptosis through PARP cleavage and caspase 3 activation from
some but not all exosome enriched preparations. Collectively, these data suggest that
exosomes from RVFV infected cells alter the dynamics of the immune cells and may
contribute to pathology of the viral infection.
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INTRODUCTION
Rift Valley Fever Virus (RVFV; Bunyaviridae: Phlebovirus)
is an enveloped virus that contains three single stranded
RNA segments. The virion is approximately 80–120 nm in
diameter (Ikegami, 2012) with a lipid bilayer envelope containing
glycoproteins Gn and Gc. The RVFV genome is tripartite and
consists of L, M, and S segments. The L and M segments,
respectively, encode for the RNA dependent RNA polymerase
(L protein) and the NSm and 78-kDa proteins and two major
envelope proteins, Gn and Gc. The S segment is of ambisense
polarity and encodes for two proteins: nucleoprotein (N) and
a non-structural protein (NSs; Pepin et al., 2010). The three
ribonucleocapsids (RNPs) are ﬁlamentous and exhibit pan-
handle like structure owing to complementary genome terminal
sequences. This acts as a promoter for genomic RNA synthesis
since they lack a 5′ cap structure. Transcription of each of the
segments utilizes a cap-snatching process by cleaving the 5′cap
from the host mRNA (Ikegami, 2012).
The critical viral protein NSs has been shown to form
ﬁlaments in the nuclei of infected cells (Yadani et al., 1999). NSs
interacts with the p44 subunit of a transcription factor (TFIIH)
responsible for transcription of cellular RNA polymerase I and
II. This interaction most likely shuts down the assembly of the
TFIIH complex, therefore resulting in general transcriptional
shutoﬀ (Le May et al., 2004). RVFV infection is known to
activate certain transcription factors (IRF-3, AP-1, and NF-κB);
however, there has also been evidence of suppression of speciﬁc
genes including the IFN-β and IFN-related genes (Billecocq
et al., 2004). NSs speciﬁcally interacts with Sin3A-associated
protein (SAP30) and forms a multiprotein complex on the IFN-β
promoter, resulting in overall suppression (Le May et al., 2008).
In addition, NSs has the capability to degrade host proteins
such as the double stranded RNA-dependent protein kinase
(PKR; Habjan et al., 2009) and TFIIH p62 (Kalveram et al.,
2011).
Exosomes are cell derived membrane bound vesicles secreted
into the surrounding extracellular environment. Exosomes were
originally considered as a vehicle to remove cellular waste from
the cytosol; however, in recent years they have been recognized
to also aid in cell–cell communication, play a critical role
in immunomodulation, and enhance infectivity during viral
infections (Colino and Snapper, 2007; Izquierdo-Useros et al.,
2010; Luga et al., 2012; Fleming et al., 2014). Exosomes are
characterized as extracellular vesicles ranging from 50 to 150 nm
in diameter and a density of 1.23–1.16 g mL−1 (Théry et al.,
2006). They are thought to originate from late endosomes
containing speciﬁc mRNAs, microRNAs, proteins, and lipids that
are then secreted into the extracellular environment (Harding
et al., 1984; Jaworski et al., 2014a; Ailawadi et al., 2015; Izumi
et al., 2015). The exact content of the exosomes vary depending
on the cellular origin; however, some of the more common
exosomal markers include CD63, Alix, and actin (Logozzi et al.,
2009).
In recent years, the role of exosomes from virally infected
cells has been explored with great interest. For instance, virally
infected cells produce exosomes with major changes in protein
composition as compared to exosomes from uninfected cells
(Meckes et al., 2013). In particular, this is demonstrated in
exosomes puriﬁed from B cells infected with Kaposi sarcoma
herpesvirus (KSHV), Epstein–Barr Virus (EBV), or cells that are
dually infected. Mass spectrometry results indicated that 871
proteins were identiﬁed and approximately 360 proteins were
unique to exosomes isolated from virally infected B cells. It is
believed that viral latentmembrane protein 1 (LMP1) upregulates
the protein content in exosomes from EBV infected cells.
These exosomes can aﬀect the interferon and NF-κB signaling
pathways, lipid raft organization, and traﬃcking of proteins. On
the other hand, the eﬀects of exosomes from KSHV infected
cells diﬀered in terms of protein translation, metabolism, and cell
migration. Additionally, exosomes released from virally infected
cells have been shown to have varying compositions of RNA
(Canitano et al., 2013). For instance, exosomes released from EBV
infected lymphoblastoid and nasopharyngeal cells contain EBV
encoded latent phase mRNAs.
RNA viruses such as retroviruses can hijack exosomal proteins
as well as other components to increase their spread throughout
the body. In addition to this beneﬁt, the resulting changes
in recipient cells that receive the exosomes can be profound,
leading to disease state and pathologies associated with an
increased infection. To this end, we have previously shown that
latent human immunodeﬁciency virus-1 (HIV-1) and human
T-cell lymphotropic virus-1 (HTLV-1) infected cells produce
exosomes with remarkable phenotypes important in cellular
activation and viral spread. For instance, HIV-1infected latent
cells secrete exosomes containing TAR RNA, a 52-base stem-
and-loop structure transcribed from the integrated provirus.
TAR RNA was found to be associated with components of
the miRNA machinery that are involved in generation of
speciﬁc 5′ and 3′ miRNAs, as well as in sera of patients on
antiretroviral drugs and long-term non-progressors (LNTPs;
Narayanan et al., 2013). The net eﬀects of these RNAs is
to act as a decoy in the recipient cells to suppresses innate
immune molecules such as PKR, and activate NF-κB through
TLR pathways (Sampey et al., 2015). A similar scenario is also
seen with HTLV-1 infected latent cells where Tax protein, a
powerful transactivator of NF-κB and CREB factors, stimulates
recipient cells, potentially leading to activation of pathways
needed for transformation (Jaworski et al., 2014a). Additionally,
HTLV-1 exosomes contain high levels of cellular miRNAs that are
bound to Ago2, but have limited amounts of Dicer and Drosha
(unpublished data). The increased level of Ago2 bound to cellular
miRNAs suggests that HTLV-1 infected exosomes can rapidly
control mRNA and their subsequent inhibition in the recipient
cells.
In the current manuscript, we asked whether cell clones
resistant to cytotoxic eﬀects of RVFV infection secreted exosomes
that could potentially regulate neighboring cells. Similar to HIV-1
and HTLV-1 latently infected cells, we generated latent resistant
clones in vitro following RVFV infection by isolating clones
that survived the infection. These resistant clones were also
resistant to subsequent RVFV infection, but not to other viruses,
including VEEV. The exosomes from these clones were enriched
and characterized for presence of viral genomic RNA and
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proteins. We found that almost all exosome-enriched secretions
from resistant clones contain viral RNA and proteins such as
N- and NSs. The net eﬀect of exosome-enriched preparations
that contained both viral RNA and protein were induction of
apoptosis in recipient cells including T- and monocytic cells.
The mechanism of apoptosis was related to regulators such
as PARP and caspase 3. The implication of how exosomes
may be controlling neighboring cells and their contribution to
pathogenesis of RVFV will be discussed.
MATERIALS AND METHODS
Cell Culture and Reagents
Vero (African green monkey kidney) cells were maintained in
Dulbecco’s modiﬁed minimum essential medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin, and 1% L-glutamine. Exosome free
DMEM was supplemented as above except FBS was ultra-
centrifuged at 100,000 × g for 70 min to remove bovine
exosomes. To generate resistant clones, Vero cells were infected
with RVFV at a multiplicity of infection (MOI) of 3. Following a
2 weeks culture (with addition of media and presence of virus in
the supernatant), the individual colonies (∼1% of cells) resistant
to infection were selected. They were isolated using sterile pipette
tips and trypsin. Clones were plated and passaged 50 times to
further purify individual clones. The assay was repeated twice,
once with the wild type MP12 and then repeated independently
with V5- and Flag-tagged-MP12 virus. In this manner, two sets of
resistant clones were isolated either containing wild type MP-12
or V5- and Flag-tagged MP-12 resistant clones.
The Jurkat T cell line was isolated from an adolescent male
patient with acute T cell leukemia (Schneider et al., 1977), while
the CEMT cell line was isolated from a juvenile female presenting
acute lymphoblastic leukemia (Foley et al., 1965). Both of these T
cell lines carry mutations within the p53 gene (Laumann et al.,
1992; Park et al., 1994; Cinti et al., 2000; Ahmadianpour et al.,
2013). The U937 monocytic cell line was derived from an adult
male patient with histiocytic lymphoma (Sundstrom and Nilsson,
1976). As with the Jurkat and CEM cell lines, the U937 cell line
also harbors mutations within the p53 gene (Sugimoto et al.,
1992; Mori et al., 1997).
Isolation of Exosomes
Resistant clones were expanded into two T-150 ﬂasks and
incubated at 37◦C for 5 days. One hundred milliliter of exosome
free DMEM was used for growth of cells. Supernatants were
centrifuged at 2,000 rpm for 10 min at 4◦C to eliminate
dead cells. Supernatants were then ﬁltered through 0.22 μm
ﬁlters to remove most apoptotic bodies, but allow viruses and
exosomes to pass through the ﬁlter. The ﬁltrate was then
processed through a series of ultracentrifugation steps. In the
ﬁrst step, ﬁltrate was ultracentrifuged at 10,000 × g for 30 min
at 4◦C. Supernatants were transferred to clean ultracentrifuge
tubes and ultracentrifuged again at 100,000 × g for 70 min
at 4◦C. Supernatants were removed and exosome pellets were
resuspended in PBS without calcium and magnesium and
ultracentrifuged again at 100,000 × g for 70 min at 4◦C. Pellets
were resuspended in 50–100 μl of sterile PBS without calcium
and magnesium. These semi-puriﬁed exosomes were stored at
4◦C for up to 2 weeks for subsequent analysis. The protein
concentrations of exosome preparations were determined by
running Bradford assays on exosomal lysates.
For exosome isolations using low volumes, we utilized
nanoparticles. Nanotrap particles NT080 and NT082 (Ceres
Nanosciences) were used in combination to enrich for exosomes.
Equal amounts of nanoparticles were mixed together (∼0.5 ml
each) and resuspended in a 30% slurry in PBS without Calcium
and Magnesium. Twenty microliters of the slurry was added
to 100–1000 μl of supernatant and rotated either overnight
at 4◦C or for 30 min at room temperature. Samples were
centrifuged at 14,000 rpm for 5 min. Supernatants were aspirated
and washed twice with PBS, and ﬁnally resuspended in 30 μl
prior to subsequent assays. The samples were used for RNA
extraction using the trizol-chloroform method or for western
blots.
Dynabeads coated with CD63 antibody (Life Technologies)
were used to purify exosomes from cell supernatant. Twenty ﬁve
microliters of the suspension of magnetic dynabeads were washed
with PBS and used for each sample. Approximately 1 ml of 5 day-
culture supernatants were added to the beads and incubated
overnight at 4◦C. The bead-bound exosomes were washed twice
with PBS and subsequently used for RNA isolation.
RT-PCR
Total RNA was extracted from diﬀerent samples including
exosomes and whole cell lysates via trizol-chloroform method.
Approximately 400 ng/μl of RNA was used from sample for
cDNA synthesis with GoScript Reverse Transcription System
(Promega) using Random Primers. Primer pairs utilized for each
segment were as follows: for M segment: Gn Forward (5′-AAA
GGA ACA ATG GAC TCT GGT CA-3′, Tm = 58◦C) and Gn
Reverse (5′-CAC TTC TTA CTA CCA TGT CCT CCA AT-3′;
Tm = 58◦C); for L segment: RVFV L Polymerase Forward (5′-
GGT GGC ATG TTC AAT CCT TT-3′; Tm = 54◦C) and RVFV
L Polymerase Reverse (5′-GCA TTC TGG GAA GTT CTG GA-
3′; Tm = 54◦C); for S segment: RVFV NSs Forward (5′-TCT
GAA AGA AGC CAT ATC CT-3′; Tm = 54◦C) and RVFV NSs
Reverse (5′-CTC GCT ATC ATC CTG TGT AA-3′; Tm = 54◦C)
and RVFVN Forward (5′-CATGGTGGATCCTTCTCTAC-3′;
Tm= 54◦C) and RVFVN Reverse (5′-CTA TTCACTGCTGCA
TTC AT-3′; Tm = 54◦C). The PCR conditions were: one cycle
at 95◦C for 2 min, 41 cycles at 95◦C for 15 s and 58◦C or 54◦C
(depending on primer set) for 40 s. The absolute quantiﬁcation
of the samples was determined based on the cycle threshold (Ct)
value relative to the standard curve. The dilutions of plasmids
containing sequences of the segments of RVFV genome cDNA
were used as quantitative standards.
Western Blot Analysis
For analysis of protein content of exosomes released from
RVFV resistant clones, exosomes were isolated via the diﬀerential
centrifugation method. Four microgram/sample were added to
SDS sample buﬀer supplemented with 10% 2-mercapthoethanol.
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Entire content of sample was loaded onto a 4–20% Tris-
Glycine gel run at 150 V, followed by overnight transfer onto
PVDF membranes. Membranes were blocked in 5% milk in
PBS plus 0.1% tween-20 for 2 h at room temperature, then
incubated overnight at 4◦C with appropriate antibody: α-CD63
(ab8219 1:500), α-N protein (generous gift or Dr. C. Schmaljohn;
USAMRIID), α-Flag (sc-807 1:200), α-Alix (sc-49268 1:150), and
α-beta actin (ab49900 1:5000).
TLR3 Assay
The HEK-293T based reporter cell line, HEK-Blue hTLR3
(InvivoGen), was used to detect activation of TLR3 by
supernatant of resistant clones. HEK-Blue hTLR3 cells contain a
secreted embryonic alkaline phosphatase (SEAP) reporter gene
that is transcribed upon TLR3 activation. Prior to adding the
HEK-Blue hTLR3 cells, experimental samples and controls were
brought up to 20 μL using PBS and distributed in a 96-well
plate. HEK-Blue hTLR3 cells were grown to 50–80% conﬂuence
in a T-75 ﬂask, washed with PBS, and then detached with 2 mL
of pre-warmed PBS and tapping the ﬂask. Cells were counted
and then resuspended to a cell density of 2.8 × 105 cells/mL
in pre-warmed HEK-Blue Detection medium (InvivoGen). Next,
180 μL of the resuspended cells were added to each of the
samples in the 96-well plate to give a ﬁnal cell count of
5 × 104 cells/well. After 18–68 h of incubation (depending on
the experimental design) at 37◦C in 5% CO2, the absorbance
(600 nm) of each control and test condition in the 96-well
plate was measured using the GloMax Multi Detection System
(Promega). Readings from all positive controls and experimental
samples were normalized using the mean reading from three PBS
negative controls.
Cell Viability Assay
Approximately 50,000–100,000 cells in 50 μl exosome free media
were plated in a 96 well plate. Fifty microliters of supernatant
from resistant clones were centrifuged 10 min at 14,000 rpm,
added to plated cells and allowed to incubate at 37◦C in 5%
CO2 for 5 days. Plate and Cell Titer Glo reagent (Promega)
were allowed to cool/thaw at room temperature for 30 min.
One hundred microliters of Cell Titer Glo reagent was added
to appropriate wells and manually shaken for 2 min, followed
by a 10 min incubation at room temperature. Counts from the
exosome free DMEM served as background and were used to
normalize values. Assays were conducted in biological triplicates.
Approximately 50,000–100,000 cells (Jurkat or U937) in 50 μl
exosome free RPMI-1640 medium were plated in a 96 well plate.
Exosomes isolated through ultracentrifugation were added at
2μg/well. Plates were incubated at 37◦C for 5 days. One hundred
microliters of Cell Titer Glo reagent were added to appropriate
wells and manually shaken for 2 min, followed by incubation at
room temperature for 10 min.
Statistical Analysis
Standard deviationwas calculated in all quantitative experiments.
P-values were calculated by the student’s t-test and considered to
be statistically signiﬁcant when p< 0.05 unless otherwise noted.
RESULTS
Generation of RVFV Resistant Clones
Exosomes are known entities that are involved in communication
between cells resulting in spread of information, including
cytokines and miRNA, some of which aid in regulating infection
of adjacent cell (Fleming et al., 2014; Kalamvoki et al., 2014). We
were interested in characterizing exosome-enriched preparations
from RVFV resistant clones that were incapable of releasing
functional virions and asked whether they could inﬂuence the
neighboring cells. We decided to generate resistant clones since
RVFV infection causes cell death in a majority of infected cell
types in vitro within 24–48 h. Therefore, we devised a scheme
to generate reliable clones that contained viral RNA and/or
proteins that could potentially be secreted from the cells as
components of extracellular vesicles, particularly exosomes. Our
rationale comes from our previous work where HIV-1 or HTLV-
1 infected resistant clones (i.e., latent cells) produced exosomes
that contained both viral RNA and/or proteins (Narayanan
et al., 2013; Jaworski et al., 2014a). Speciﬁcally, we infected
Vero cells with RVFV at MOI of 3 and allowed the cells to
incubate for 10–14 days at 37◦C days and checked for presence
of small surviving resistant clones. These cultures contained
individual patches of resistant cells despite having high virus
titer in the media. Following 2 weeks incubation, plates were
washed and cells were removed using a micropipette with a
solution of trypsin and diluted in a microtiter plate to achieve
a 1–10 cell/well cultures (Figure 1A). We created 90 resistant
clones using this dilution cloning procedure. These cells were
next expanded and supernatants (5 days incubation at 37◦C)
were added to TLR3 indicator cells. We and others have
previously shown that molecules within the exosomes activate
various cascades of signal transduction as evident by increase
in pro-inﬂammatory cytokines mediated by TLRs (Bhatnagar
and Schorey, 2007; O’Neill and Quah, 2008). We focused on
seven of 90 clones that were amongst the top 30 activators
of the TLR3 reporter cell line and survived 50 subsequent
passages to increase their clonal purity (Figure 1B). To further
assure that the passaged clones were truly resistant to infection,
they were re-infected with RVFV (MOI: 3). After 48–72 h,
none of these clones demonstrated signs of cell death following
secondary viral infection. However, all of the clones were sensitive
to secondary infection by another cytoplasmic RNA virus,
the Venezuelan Equine Encephalitis Virus (data not shown).
We ﬁnally performed a set of conﬁrmatory assays including
RNA PCR to validate presence of RVFV genome in these
clones (see below). Collectively, these data imply that RVFV
infection can allow generation of cells that are resistant to RVFV
infection.
Presence of RVFV Genome in Resistant
Clones
We next asked whether these resistant clones contained RVFV
genome within the cells. We also asked whether viral genome
levels were altered following a second RVFV infection of these
cells. Our rationale for these experiments was that if these clones
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FIGURE 1 | Generation of Rift infected resistant clones. (A) Vero cells were infected with RVFV at MOI 3. Approximately 1% of cells survived the infection and
isolated using trypsin diluted with PBS. Clones were plated and passaged 50 times before characterization. (B) The HEK-293T based reporter cell line, HEK-Blue
hTLR3 (InvivoGen), was used to detect activation of TLR3 by supernatant of RVFV resistant Vero cells. After 18 h of incubation at 37◦C in 5% CO2, the absorbance
(600 nm) of each control and test condition in the 96-well plate was measured using the GloMax Multi Detection System (Promega). Readings from all positive
controls (sample 2, 10 ng/mL Poly I/C) and experimental samples were normalized using the mean reading from three sterile water treated negative controls. Seven
clones (as indicated) were selected for follow up experiments. Error bars on the first two samples (negative and positive controls) indicated ±1 SD of biological
triplicates.
were resistant to a new incoming virus replication, the overall
dynamics of the intracellular RVFV genomes in these clones
should not change drastically. Total RNA was extracted from
the clones and cDNA was generated by RT reaction and then
quantitated by real-time PCR. A qRT-PCR analysis of cellular
RNA from clones prior to and after infection was performed
using primer pairs for each of the three viral segments. The
primers speciﬁc for the polymerase gene detected L segment;
Gn gene-speciﬁc primer set detected the M segment; and,
the S segment was detected using the primers for both N
and NSs genes. Results of qRT-PCR indicated that all clones
contained intracellular M, L, and S segments of viral genomic
RNA; however, varying levels of the NSs RNA were present
in few of the clones (Figure 2A). More importantly, when
these cells were incubated with RVFV again and carried for
10 days, there were no dramatic changes in the genome
content of the resistant clones (Figure 2B), indicating that
these clones maintain viral genome integrity without much
alteration after a new round of cell duplication or infection.
Collectively, these results imply that the resistant clones carry
RVFV genome and the cells are resistant to apoptosis and re-
infection by RVFV.
We next asked whether we could isolate resistant clones again,
this time using another RVFV strain that has been reconstructed
to contain epitope-tags in the viral genome. The clone epi-
RVFV contains V5-tagged L, and C-terminal Flag-tagged NSs.
The virus was synthesized by reverse genetics and was replicated
in Vero cells to obtain high titers (generous gift of Drs. Terasaki
and Makino, UTMB). Again, similar to experimental design in
Figure 2, Vero cells were infected with wild type epi-RVFV and
resistant clones were isolated and screened using TLR3 indicator
cells. Results in Figure 3A indicate that resistant clones were
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FIGURE 2 | Presence of RVFV genome in resistant clones. (A) Total RNA was extracted from seven RVFV resistant Vero cells using the trizol-chloroform
method. For each sample, approximately 400 ng/μl of RNA was used for cDNA synthesis with GoScript Reverse Transcription System using Random Primers. The
absolute quantification of the samples was determined based on the cycle threshold (Ct) value relative to the standard curve. (B) qRT-PCR analysis of resistant
clones 10 days after secondary infection with RVFV at MOI 1.
able to survive viral infection and subsequently few of the clones
were isolated for passages and dilution cloning. Four clones were
chosen for the characterization mainly due to ease of isolation
and maintenance of clones in cell culture for an extended period
of time. We next asked whether these second generation clones
contained intracellular viral RNA. Results in Figure 3B indicate
that all of the second generation resistant clones contained viral
RNA, albeit at varying levels. For instance, the genomic RNA in
clone #1 contained more L polymerase gene as compared to other
clones; clone #21 had the highest level of Gn RNA. These results
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demonstrate that the resistant clones infected with epitope-
tagged RVFV carry genomic RNA similar to the untagged (ﬁrst
generation) resistant clones.
We next isolated exosomes from the second generation
clones using diﬀerential centrifugation and compared their
RNA content with exosomes from the ﬁrst generation un-
tagged clones. Results in Figure 3C indicate that indeed
the exosome-enriched preparations contained viral RNA in
both sets of ﬁrst and second generation clones. Interestingly,
the overall levels of RNA in exosomal preps were less
than the intracellular RNAs. Two clones, H6 from ﬁrst
generation and #14 from the second generation, showed the
highest level of genomic RNA (all four) in the exosome-
enriched preps. Finally, using a well-known exosomal membrane
marker (i.e., CD63), we further puriﬁed the exosomes from
supernatants and characterized for presence of viral RNA.
FIGURE 3 | Continued
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FIGURE 3 | Presence of RVFV genomic RNA in exosomes. (A) Vero cells were infected with double tagged RVFV for recovery of resistant clones as described in
Figure 1. Resistant clones were isolated and screened on TLR3 indicator cells. (B) qRT-PCR of second generation clones was used to detect presence of RVFV
genome in cell lysates. The analysis was performed as described in Figure 2A. (C) Exosome-enriched preparations were isolated from first and second generation
clones via differential ultracentrifugation method. Total RNA was extracted to test for the presence of RVFV genome. (D) Exosomes were isolated from first and
second generation clones through co-immunoprecipitation of cell supernatants using CD63 Dynabeads. Total RNA was extracted to test for presence of RVFV
genome.
Results in Figure 3D indicate that exosomes obtained using
CD63-immunoprecipitations (IP with Dynabead – CD63) also
contained viral RNA, similar to the diﬀerential centrifugation
method normally used for exosomal preparation. Interestingly,
the overall levels of exosomal CD63-IP viral RNA almost
mimicked the exosomal isolation using centrifugation procedure,
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but contained one log more in the overall RNA contents.
Collectively, these results imply that Rift RNA is present not only
in intracellular compartment of the resistant clones but also in
exosomes.
Effect of Exosome-Enriched Materials on
Recipient Cells
We and others have previously shown that exosomes from
latently HIV-1 or HTLV-1 infected cells are capable of controlling
survival of recipient uninfected cells (Lenassi et al., 2010;
Narayanan et al., 2013; Aqil et al., 2014; Jaworski et al.,
2014a). The eﬀects were largely due to either viral proteins or
RNA present in their exosomes. Here, we asked whether the
exosome-enriched preparations obtained from the Rift resistant
clones also were able to control cell survival in recipient
cells.
We designed two sets of experiments on indicator cells using
either supernatants or concentrated exosomes. Approximately
50–100,000 cells were plated in a 96 well plate and supernatants
from resistant clones (A8, C6, E1, E5, E6, E12, and H6) and Vero
control cells were added to cells and allowed to incubate at 37◦C
for 5 days. Viability was subsequently assayed using CellTiter-
Glo. Results in Figure 4A indicate that culture supernatants from
various ﬁrst generation clones had no eﬀect on Vero cells after
5 days of culture, perhaps due to the fact that initial clones were
obtained from Vero cells. These exosome-containing materials
were then added to lymphocytes or monocytes for 5 days. No
additional culture supernatant or media was added during the
experiment. Results in Figure 4A indicate that viability of all
three cell types was altered with the exosome-containing culture
supernatants s from certain clones, including E12, H6 and E5.
Interestingly clone H6 showed the most consistent result among
all three indicator cells.
We next enriched exosomes through diﬀerential
centrifugation from both selected ﬁrst and second generation
clones, treated target cells and performed cell viability assay
on both lymphocytes and monocytes. Results in Figure 4B
indicate that clones H6 and #14 were eﬀectively inhibiting
cell viability in both cell types following 5 day-incubation.
Interestingly, clones H6 and #14 contain high levels of all four
RNAs from RVFV. Other clones including #1, 21, and 36 had
lower levels of all RNAs with minimal cell death. Clone E1
had lower N and NSs levels with minimal death and clone E5
was missing Gn altogether with no apparent cell death. Finally,
it is important to note that all of these cells were sensitive to
infections with other RNA viruses including VEEV. For this
we performed another set of experiments where we treated
both clone H6 and #14 with RVFV and VEEV and kept the
cultures at 37◦C for 5 days. Results in Figure 4C indicate that
both clones were resistant to RVFV infection but sensitive to
VEEV infection. Positive control Vero cells were sensitive to
both RVFV and VEEV infection, indicating that resistant clones
were still sensitive to other RNA viral infections but not to the
original parent virus. Overall, these results suggest that the death
of recipient cells may be related to high level of viral RNA in
exosomes.
Presence of Viral Proteins in
Exosome-Enriched Preparations
Presence of Rift viral RNA promoted us to ask whether viral
proteins were also present in these exosome preparations. We
performed western blots against two critical viral proteins: N and
NSs. Antibody against N protein was readily available (generous
gift of Dr. Connie Schmaljohn, USAMRIID) and we also utilized
anti-FLAG- antibody to detect NSs protein. Results in Figure 5A
indicate that clones E1, E5, H6, and #14 contained varying
amounts of N protein in the exosome-enriched materials. The
presence of N protein was independent of N RNA, as apparent in
clones #1, 21, and 36. Other exosomal markers including CD63,
Alix, and actin were expectedly present in all tested clones.
Finally, we asked whether NSs protein was also present in
these preparations. We used only second generation clones
using epi-tag antibody for these experiments which allowed
probing for the FLAG tag as an indication of the presence of
NSs. Results in Figure 5B indicate that NSs was present in
three out of four preparations; however, the intracellular NSs
(from Rift virus infected cells) were mostly unmodiﬁed whereas
the NSs protein in the exosome-enriched preparations showed
a protein of a slightly higher molecular weight. We recently
have obtained data from both HIV-1 and HTLV-1 exosomes
indicating that many critical viral proteins may be modiﬁed
including ubiquitination (unpublished results). Therefore, we
performed a series of immunoprecipitation (IPs) from our
exosomes using anti-ﬂag antibody directed toward NSs, followed
by western blot using anti-ubiquitin antibody. Our rationale
for these experiments, as stated above, were that NSs might
be ubiquitinated in these exosomes as we ﬁnd most proteins
expressed and packaged into exosomes potentially modiﬁed
including ubiquitination (data not shown). Results in Figure 5C
indicate that there are various forms of the modiﬁed NSs in
the exosomes when using anti-ﬂag antibody. Although IgG
control immunoprecipitation did bring down some non-speciﬁc
proteins, there were more bands in the anti-ﬂag IPs from the
four exosome clones used in the assays. Interestingly, there were
less of the ubiquitin-NSs in clone #36 as compared to others.
Collectively, these data imply that certain exosomes contain not
only viral RNA but also varying levels of viral N andmodiﬁedNSs
proteins.
Effect of Exosome on the Recipient Cell
Apoptosis Machinery
We next asked whether classical markers of apoptosis were
present in the recipient cell extracts treated with exosome-
enriched populations. We performed western blots for markers
PARP, caspase 3, as well as PKR degradation, a known marker
of NSs target in cells (Habjan et al., 2009). We treated both
T-cells (Figure 6A) and monocytes (Figure 6B) for 5 days
and subsequently obtained whole cell extracts for western
blot analysis. We used either Rift infection (MOI = 0.1) or
uninfected Vero exosomes as positive and negative controls.
Our rationale for these experiments were based on the fact
that Cell Titer Glo assay alone (data in Figure 4) does not
diﬀerentiate between various stages of cell viability. Data in
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Figure 4A indicate that PARP and Caspase 3 cleavage was
mostly seen in recipient T-cells treated with exosome clone
#14. This was also somewhat consistent in monocytes treated
with clone #14 exosomes (Figure 4B). Interestingly, clone
H6 treated cells didn’t show appreciable levels of PARP or
Caspase 3 cleavage in either of the cell types, indicating that
FIGURE 4 | Continued
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FIGURE 4 | Effects of exosomes on recipient cells. (A) Approximately 50,000–100,000 cells in 50 μl exosome free media were plated in a 96 well plate. Fifty
microliters of supernatant from resistant clones (A8, C6, E5, E12, and H6) and Vero cells were centrifuged 10 min at 14,000 × g. Then 50 μl of supernatants were
added to cells and allowed to incubate at 37◦C for 5 days. Viability was subsequently assayed using CellTiter-Glo assay and values for exosome-free DMEM (control)
were used to subtract background. Samples treated with supernatant from uninfected Vero cells were set to 100% and used to normalize the experimental values.
The assay was conducted using biological triplicates and error bars indicate ±1 SD. (B) Exosomes were isolated through differential ultracentrifugation and 2 μg was
added to 50,000–100,000 cells in a 96 well plate. Cells were allowed to incubate at 37◦C for 5 days and viability was subsequently assayed using CellTiter-Glo
assay. Again, values for exosome-free DMEM (control) were used to subtract background and samples treated with exosomes from uninfected Vero cells were set to
100% and used to normalize the experimental values. The assay was conducted using biological triplicates and error bars indicate ±1 SD. (C) Approximately
100,000 mid-log Vero cells, H6 or clone #14 were treated with either RVFV or VEEV (TC83) at MOI = 1 and incubated at 37◦C for 5 days. Samples were processed
for cell viability using CellTiter-Glo in a microtiter plate. Triplicate samples were treated with either of the two viruses. ∗p < 0.05.
the mechanism of action for these two clones may be very
diﬀerent in treated recipient cells. Finally, for treatment with
clone #14, the degradation of PKRwasmuchmore pronounced in
monocytes as compared to T-cells, implying that the NSs activity
may be higher in these cells. Collectively, these results imply
that exosome treated recipient cells may undergo a generalized
apoptosis.
Effect of Resistant Clone Supernatants
on Vero and Immune Cells
We next asked whether the apoptosis observed in the immune
cells (Figure 4) were the result of potential presence of mutant
viruses contaminating our resistant clone preparations. This is
critical since most of the exosomes obtained and characterized
to date (clones H6 and #14) do contain characteristics of a
potential virus (i.e., mutant) in the supernatants. We therefore
designed experiments where we added unprocessed supernatants
from the resistant clones to normal Vero cells (susceptible to
Rift infection) and carried these cells for 3 weeks. Unﬁltered
supernatants from both clones H6 and #14 were then added to
fresh Vero cells and washed 24 h later. Fresh media was added
and samples (both supernatants and cells) were collected at the
end of weeks 1, 2, and 3. The cells at the end of week 1 and
2 were split 1:3 to avoid over growth in plates. Independent
supernatants from week 0 (starting material) and weeks1, 2, and
3 were treated with nanoparticles NT080, NT082 (to concentrate
exosomes) and NT086 (to concentrate potential virus) prior to
qPCR for presence of Rift genome. We have previously shown
that dilute viral or exosomal samples can be concentrated and
enriched using speciﬁc nanoparticles (Jaworski et al., 2014b).
Data in Figure 7A shows that Rift RNA was present in the
resistant clone supernatants (starting material; S0) and almost
completely absent in supernatants from treated Vero cells in
weeks 1–3 (S1–3). We also looked at the intracellular RNA level
from these treated cells and found that the Rift RNA was only
present in week 1 samples and completely absent in weeks 2
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FIGURE 5 | Presence of viral proteins in exosomes. (A) Enriched
exosomes were isolated through differential centrifugation and were analyzed
by Western Blotting with antibodies to N protein (generous gift from Dr.
Connie Schmaljohn; 1:500), CD63 (ab8219 1:500), Alix (sc-49268 1:150), and
Actin (ab49900 1:5000). (B) Exosome-containing preparations obtained from
resistant clones and corresponding WCEs were analyzed by Western Blots
with antibodies to NSs Flag (sc-807 1:200) and Ubiquitin (1:500). (C) Three
hundred and fifty microgram of purified exosomes was used for lysis, using
Freeze-Thaw and TNE 50 + 0.1% NP-40 and immunoprecipitation using
either IgG or anti-flag antibody (10 μg each). Samples were IPed overnight;
protein A + G beads added (30% slurry) the next day for 2 h, centrifuged and
washed. Bound samples were run on a gel for western blot using
anti-ubiquitin antibody (1:500). Black circles indicate potential Ubiquitinated
NSs proteins present in the exosomes.
and 3 samples (Figure 7B). Cells at weeks 1–3 were actively
growing as evident by duplication and presence of GAPDH.
We next asked whether exosomes from clone #14, that were
involved in the induction of apoptosis in immune recipient
cells, had the capacity to replicate their genomic RNA in these
cells. Our rationale for these experiments is based on data
demonstrating that exosomes from HCV infected cells contain
viral genomic RNA that can enter into uninfected cells and
replicate independent of its speciﬁc receptor (Masciopinto et al.,
2004; Bukong et al., 2014). This would be in comparison to
an active viral replication, where viral RNA replicates to ∼106
copies in 24–48 h after infection. Therefore, we treated both
Jurkat and U937 cells with clone #14 or control exosomes
from uninfected Vero and isolated total RNA at 2 and 4 days
followed by qRT-PCR for presence of viral genomic RNA.
Results in Figure 7C indicate that the Rift RNAs did not
replicate in either cell type, further implying that components
of replication machinery may be missing in these exosome-
enriched samples, hence resulting in an eventual loss of genomic
RNA in the recipient cells. Collectively, these data further imply
that the resistant clones do not contain mutant viruses that
could potentially replicate with slower kinetics in susceptible
cells.
Effect of RVFV on Immune Cells
One of the fundamental questions regarding our work on
exosomes is whether exosomes released from infected cells
could play a critical role in the pathology of the disease
in comparison to the viral release. This is an important
question, since viral infection usually results in release of high
titer viruses over a period of time which may overwhelm
and mask any potential exosomal eﬀect on the recipient
cells. Along these lines, data in Figures 4 and 7 indicate
that exosomes can regulate the recipient immune cells and
cause apoptosis over a period of time. However, it was
not clear to us whether RVFV could also cause apoptosis
of immune cells in vitro. To answer this, we performed
an experiment where T-cells (Jurkat) and monocytes (U937)
were treated with two concentrations of RVFV (MOI = 0.1
and 1.0) and incubated with the virus for 5 days. In our
initial set of experiments, we monitored these cells everyday
by microscopy and trypan blue staining (data not shown).
Subsequently quantitative experiments were performed in
microtiter plate and assayed for viability using CellTiter-
Glo assay. Interestingly, we observed complete resistance of
the immune cells to apoptosis by RVFV over an extended
period of time (Figure 8A). As expected, positive control
Vero cells were apoptosed following infection. This is also
reﬂected in the cell morphology as shown in Figure 8B
where Vero cell monolayers were rounded up following RVFV
infection but no apparent cellular changes were observed in
T-cell and monocytes. Collectively, these results imply that
immune cells may be resistant to RVFV-induced apoptosis,
whereas exosomes could potentially target immune cells for
destruction. This dual action of viral infection of speciﬁc
target cells and apoptosis of immune cells from exosomes
could contribute to the overall pathology of RVFV infection
in vivo.
DISCUSSION
In recent years, exosomes have emerged as essential and
critical components of intercellular communication during
viral infection related to disease states, including cancers and
spreading of the viral infections. We have previously shown
that exosomes from virally infected latent cells have the ability
to control gene expression and cell viability in the recipient
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FIGURE 6 | Effect of exosomes on the recipient cell apoptosis machinery. (A) Jurkat cells treated with exosome-enriched preparations from resistant clones
were analyzed by Western blotting with antibodies to markers of apoptosis, which included Caspase 3 (sc-7148 1:200), PARP (sc-7150 1:200), and PKR (sc-707
1:200), or Actin (ab49900 1:5000). (B) U937 cells were treated similar to (A) and extracts were used for western blot analysis probing for the same apoptosis
markers.
cells (Narayanan et al., 2013; Jaworski et al., 2014a). Here, we
tested whether Rift infected cells could also secrete exosomes
that may be able to control the fate of the recipient cells.
We utilized a scheme to generate reliable clones that survived
RVFV infection and that their exosomes contained potential
viral RNA and/or proteins. Using in vitro infection of Vero
cells, we were able to generate multiple resistant clones that
could be passaged up to at least 50 times and still retained both
viral RNA and proteins in the exosome-enriched preparations.
We performed these experiments in two independent sets
of infections: with wild type MP12 and with an epitope-
tagged MP12. Using TLR3 as an initial read out assay, we
obtained clones that produced exosome-containing secretions
in 5 day-cultures that contained varying levels of genomic
RNA and viral proteins. These clones could be grown to large
scale, which simpliﬁes puriﬁcation schemes for downstream
functional assays. Interestingly, these clones were all resistant
to Rift infection, but not to other viruses including VEEV,
indicating that the mechanism of resistance may be unique
and not general for most incoming RNA viruses. These data
also indicate that the Rift replication/transcription machinery
must still be somewhat intact in these resistant clones, as
both RNA and proteins were present after continuous passage
and replication. It is therefore tempting to speculate that the
viral assembly in these cells may be blocked, and/or that
there is a competition between viral or exosomal release as
both entities presumably utilize the same exit machinery. The
broader implications are that if a cell is deﬁcient in one
Frontiers in Microbiology | www.frontiersin.org 13 February 2016 | Volume 7 | Article 139
Ahsan et al. Exosomes from RVFV Resistant Cells
FIGURE 7 | Effect of resistant clone supernatants on Vero cells. (A) Supernatants (1 ml) from clones H6 and #14 were added to Vero cells (2.5 × 106/ml in
complete media in a 24 well plate; ∼35% confluency) overnight, washed 24 h later and supplemented with complete media. Each week, supernatants (1 ml) were
collected and concentrated using mixture of nanoparticles NT080 + NT082 (to concentrate exosomes; 50 μl of 30% slurry) and NT086 (to concentrate potential
virus; 50 μl of 30% slurry) overnight at 4◦C. Samples were pelleted the next day, washed, and total RNA was isolated for qRT/PCR. “S0” denotes the starting
material and “S1–3” was supernatants from treated Vero cells in weeks 1–3. (B) Similar to (A), except that the total RNA was isolated from the cell pellets prior to
qRT/PCR for Rift RNAs. GAPDH served as internal control for RNA expression. (C) Total RNA was isolated from Jurkat and U937 cells treated with
exosome-containing preparations from Vero or resistant clone #14 after 2 and 4 days. qRT-PCR analysis were conducted with primers specific for NSs.
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FIGURE 8 | Effect of RVFV infection in immune cells. (A) Immune cells including T-cells (Jurkat) and monocytes (U937) were grown to log phase of growth in
complete media (1.5 × 106 cells/ml). RVFV (epitope-tagged MP12) at MOI of 0.1 and 1.0 were used for infection of immune cells and Vero cells as a positive control.
Cultures were incubated for 5 days as 37◦C (without removing the virus) and cell viability were assayed using CellTiter-Glo. Results in (A) are from three independent
experiments. Similar results were also observed with the wild type un-tagged MP12 (data not shown). (B) Similar to (A) except cells infected at MOI of 1 after 5 days
were used for cell morphology using light microscopy.
of the many components of the ESCRT (release) pathway,
or cells which contain mutant viral genome for release,
or cells that are under drug selection pressure, they might
collectively favor exosomal release containing viral components
over viral progeny formation and release. Future experiments
using the CRISPR system as well as mutant viruses in
various ORFs could potentially better deﬁne these overlapping
mechanisms.
Previous work with HCV (Masciopinto et al., 2004)
demonstrated the presence of viral RNA in exosomes released
from infected cells. These exosomes spread viral infection
to the neighboring cells, indicating that the genomic RNA
was capable of replicating in cells. We asked whether the
same ﬁndings may be true for the RVFV resistant clones.
Consistent with our previous work from HIV-1 and HTLV-1,
we were unable to observe Rift replication in the recipient
cells, indicating that the full replication machinery is not
transferred in these exosome-containing secretions. Therefore,
HCV RNA transfer in exosomes may have a diﬀerent packaging
set of signals compared to other nuclear or cytoplasmic viral
RNAs, which may cause it to transfer complete replication
machinery through exosomes. We also performed a time
course study where supernatants from resistant clones were
added back to uninfected Vero cells. These cells survived
replication for the duration of the study (3 weeks) and did
not produce wild type viral progeny. Importantly supernatants
from these newly treated cells did not show presence of
viral RNA or virus in the supernatants. We did, however,
observe cell associated viral RNA (10-fold less) in samples
from week 1, which may be due to presence of the input
exosomal RNA or a very slow growing mutant virus population.
Either way, the eﬀect on host Vero cells were not deemed
signiﬁcant compared to the results from immune Jurkat
and U937 cells which showed apoptosis when treated for
few days.
Using HIV-1 as our model system for presence of viral RNA
in exosomes (Narayanan et al., 2013), we have recently observed
binding and activation of number of TLRs to these RNAs when
using the exosomes from latently infected cells (Sampey et al.,
2015). Here, we used a functional TLR3 assay as a generic readout
for TLR and NF-κB activation. We consistently have observed
activation of TLR3 in these assays when using exosomes obtained
from resistant clones. This further suggests that the exosomal
cargo may have functional properties in the recipient cells,
including activation of signal transduction for genes involved in
cell fate.
Our individual clones also demonstrate a role in apoptosis
of recipient cells that may depend on the expression of viral
RNA and proteins. For instance, clone H6 shows appreciable
amounts of all RNAs and some N protein whereas clone
#14 contained viral RNAs as well as increased N protein
levels and NSs. We currently cannot rule out whether NSs
protein is present in clone H6 due to lack of antibody;
however, the overall eﬀect may result in delayed apoptosis
compared to clone #14 with higher levels of detectable NSs.
It is important to note that treatment with exosomes from
clone #14 exhibits all the classical signs of Rift infection in
recipient cells, including presence of apoptosis markers and PKR
cleavage. Although we cannot rule out the presence of other viral
proteins in clone #14, presence of all viral RNAs, N, and NSs
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protein may be responsible for apoptosis in both T-cells as well as
in monocytes.
Our data using resistant clones clearly suggest that exosomes
from infected cells may contain viral RNA and proteins. The net
eﬀect of these exosomes may be multidimensional, but at least
some may be capable of inducing apoptosis in uninfected cells.
We speculate that Rift infection in vivomay also allow formation
of exosomes that persist for an extended period of time. Whether
those exosomes contribute to the overall pathology of animals or
humans is not clear; however, they could potentially play a role
in compromising the immune system which would then allow
for better replication of the virus. In essence, these vesicles could
act as a “decoy” to dampen the innate (or potentially acquired)
immune response in hosts for a rapid viral spread. Alternatively,
they could contribute to death of not only adult immune cells
but also pluripotent stem cells, resulting in the spontaneous
abortion observed in animals. Our unpublished data using either
virus or exosomes on human stem cells point to this direction.
Future experiments using animal models and inhibitors that
allow blocking of exosome formation from infected cells may
uncover their true potential in pathogenesis in vivo.
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